FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments, including anti-infectives, gastroenterology, ophthalmology, anti-diabetics, cardiovascular care, respiratory care, gynaecology, dermatology, paediatrics, analgesics, vitamins, and nutritional health in the form of tablets, capsules, oral liquids, ophthalmic drops, topical preparations, and paediatric-friendly solutions. It also provides functional food, such as flavoured oral rehydration solution powders, ready-to-drink electrolyte beverages, vitamin-enriched supplements, antioxidant blends and protein-fortified drinks; and various active pharmaceutical ingredients. The company sells its products under the Zifi, Zifi-0, Zocon, Mycoderm, Zathrin, Victofol, Cotaryl, Ziglim-M, Amodep-AT, MumMum 1, Victofol Injection, Simyl MCT, Victofol " C, Electral, and Enerzal brands. It also exports its products to approximately 50 countries. FDC Limited was founded in 1936 and is based in Mumbai, India.
Research context
FDC Limited appears in PyInvesting’s India Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Visit company website
5 years, 6 months ago
FDC Limited is currently in a long term uptrend where the price is trading 10.4% above its 200 day moving average.
From a valuation standpoint, the stock is 24.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.6.
FDC Limited's total revenue rose by 5.9% to $3B since the same quarter in the previous year.
Its net income has increased by 1.5% to $752M since the same quarter in the previous year.
Finally, its free cash flow fell by 15.7% to $1B since the same quarter in the previous year.
Based on the above factors, FDC Limited gets an overall score of 4/5.